| Literature DB >> 35935051 |
Anjali Kandiruthi Ravi1, Saradhadevi Kuppusami Muthukrishnan1.
Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). It is an auto-immune disorder. Its usual symptoms are unique to each person. In MS lesions vast fractions of pyruvate molecules are instantly transformed into lactate. This reprogramming mechanism of glycolysis is known as the Warburg effect. MS has no efficient treatment yet. Hence, there is a requirement for profitable immunomodulatory agents in MS. Probiotics perform as an immunomodulator because they regulate the host's immune responses. Its efficacy gets enhanced for an extended period when it combines with prebiotics. In this review, we focus on the metabolic alterations behind the MS lesions via the Warburg effect, and also suggesting, the combined efficacy of prebiotics and probiotics for the effective treatment of MS without side effects. The Warburg effect mechanism intensifies the infiltration of activated T-cells and B-cells into the CNS. It provokes the inflammation process on the myelin sheath. The infiltration of immune cells can be inhibited by the combination therapy of probiotics and prebiotics. By this review, we can recommend that the idea of this combinational therapy can do miracles in the treatment of MS in the future. ©2022 The Authors.Entities:
Keywords: Medicinal plants; Multiple sclerosis; Prebiotics; Probiotics; Warburg effect
Year: 2021 PMID: 35935051 PMCID: PMC9348531 DOI: 10.34172/apb.2022.057
Source DB: PubMed Journal: Adv Pharm Bull ISSN: 2228-5881
Figure 1
Figure 2Role of different Signaling pathways in MS
|
|
|
|
| WNT/Catenin pathway | Release of cytokines by CD4+ Th17 cells. |
|
| JAK/STAT | Functioning and development of both adaptive and innate immunity. |
|
| PI3/AKT/mTOR | T-cell activation, proliferation, metabolism and apoptosis. |
|
| NF-kB | Maturation of immune cells and production of inflammatory mediators. |
|
Effect of natural compounds in MS
|
|
|
|
|
|
|
| Adult female Lewis rats (150-200 g) | Experimental autoimmune encephalomyelitis (EAE) (animal model of MS) |
Reduces the oxidative stress |
|
|
| Randomized placebo-controlled, double-blind parallel group study of 160 MS patients | MS | Effective for spasticity associated with MS |
|
| Epigallocatechin-3-gallate | Randomized, double-blind, placebo-controlled, crossover trial of 18 MS patients | Relapsing-remitting MS | Improves muscular metabolism to a greater extent in men than in women |
|
|
| 8-week-old C57BL/6 mice | EAE | Inhibits oxidative stress and prohibits leukocyte infiltration to CNS |
|
|
| Female 6- to-8-week age C57BL/6 mice | EAE | Reduces the infiltration of inflammatory cells into the CNS |
|
|
| Randomized double-blind placebo-controlled trial of 25 patients | Relapsing-remitting MS | Reduces the chronic fatigue |
|
|
| 13.5 days pregnant females mice or pups | Oligodendrocytes (OLs) primary culture systems | Enhances oligodendrocytes development |
|
|
|
Antibacterial activity against the strains of | Bacterial triggers of MS |
Inhibits the growth of |
|
|
| Clinical trial of 80 MS patients | Relapsing remitting MS | Improves the visual and spatial memory. |
|
|
| Nineteen C57BL/6 female mice- weighing 18-20g (7-to 9 week-age) | EAE | Down-regulates the production of IFN-γ and IL-17 and up-regulates the anti-inflammatory IL-10 |
|
| Saffron | Adult male Wistar rats (200-250 g) | Ethidium bromide induced demyelination | Improves spatial learning memory and antioxidant enzyme activity |
|
| Resveratrol | Male C57Bl/6 mice (20-25 g) | Cuprizone induced demyelination | Improves mitochondrial function, remyelination, motor coordination reduces oxidative stress by enhances the expression of Olig1 gene and inhibited NF-κB signaling pathway |
|
| Resveratrol | Female SJL/J mice (6-week age) | EAE | Exhibits neuro-protective activity by the activation of SIRT1 mechanism |
|
|
| Randomized clinical trial of 144 MS patients | MS | Improves pain relief and muscle stiffness in MS patients |
|
|
| Rat embryonic hippocampal neuron- from 17-days pups | Primary hippocampal neuron cell culture study | Protects axon degradation by inhibiting microglial MyD88/p38 MAPK signaling and nitric oxide production |
|
Probiotics against MS
|
|
|
|
|
|
|
|
Clinical trial: MS subjects with glatiramer Acetate treatment - 7 | Relapsing-remitting MS | Inhibits the infiltration of intermediated monocytes into the CNS |
|
|
| Female Lewis rats 6–8-week age | Experimental auto immune myasthenia gravis |
Reduces the CNS inflammation |
|
|
| Female mice wild-type (WT) C57BL/6 (10 weeks-age) | EAE | Reduced TH1/TH17 cells and their associated cytokines IFN-g/IL-17 |
|
|
| Female C57BL/6 mice (8–10 weeks age) | EAE | Improved the state of CD4+CD25+Foxp3+-expressing T-cells in the spleen and the lymph nodes |
|
|
| Double-blind randomized controlled two-group parallel Clinical trial of 50 MS patients | MS | Reduces CNS inflammation, fatigue, pain and oxidative stress |
|
|
| Randomized, double-blind, placebo-controlled clinical trial of 40 MS patients | MS | Down regulates the gene expressions of IL-8 and TNF-α |
|
|
| C57BL/6 mice (6–8 weeks-age) | EAE |
MOG-reactive T cell propagation and pro-inflammatory cytokine levels are reduced and improving IL10+ or/and Foxp3+ Treg cells. |
|
|
| 32 male Wistar rats | Ethidium bromide induced demyelination | Improves the spatial memory and learning. |
|
|
| Randomized, double-blind, placebo-controlled clinical trial of 60 MS patients | MS | Shows improvements in expanded disability status scale, mental health and HDL- cholesterol levels. |
|
|
| Randomized, double-blind, placebo-controlled clinical trial of 48 MS patients | MS | Decreases the levels of hsCRP and IL-6 and increased the anti-inflammatory cytokine IL-10 |
|
|
| Female SJL/J mice, (6–9 weeks age) | MBP83–99 peptide immunized MS model | Inhibited the secretion of pro-inflammatory cytokines IL-1β and IFN-γ and enhances the secretion of anti-inflammatory cytokines IL-4, IL-5, IL-10 |
|